You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MET Overexpression

Showing 1 - 25 of 1,711
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

Specific Protein Overexpression in Adult Non-Small Cell Lung

Not yet recruiting
  • Non Small Cell Lung Cancer
    • (no location specified)
    Sep 29, 2023

    Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))

    Completed
    • Colorectal Cancer Metastatic
    • C-met Overexpression
    • Tivantinib (ARQ197)
    • Rozzano, Milano, Italy
      Istituto Clinico Humanitas
    Sep 8, 2022

    Advanced Gastric Adenocarcinoma Trial in Seoul (AZD6094, Docetaxel)

    Completed
    • Advanced Gastric Adenocarcinoma
    • Seoul, Seoul, Korea, Republic Of, Korea, Republic of
      Samsung Medical Center
    Dec 26, 2019

    Advanced Gastric Adenocarcinoma Trial in Seoul (AZD6094, docetaxel)

    Completed
    • Advanced Gastric Adenocarcinoma
    • Seoul, Seoul, Korea, Republic Of, Korea, Republic of
      Samsung Medical Center
    Jun 13, 2022

    Stomach Cancer, Adenocarcinoma Trial in Seoul (Durvalumab, Savolitinib)

    Recruiting
    • Stomach Cancer, Adenocarcinoma
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Jan 10, 2023

    Tumor, Solid Tumors Trial in Camperdown, Liverpool (HS-10241)

    Completed
    • Neoplasm
    • Solid Tumors
    • Camperdown, New South Wales, Australia
    • +1 more
    Jul 18, 2022

    NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

    Not yet recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • Seoul, Gangnam-gu, Korea, Republic of
      Samsung Medical Center
    Oct 27, 2023

    Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7 Trial in Houston (ABBV-399)

    Completed
    Has Results
    • Recurrent Squamous Cell Lung Carcinoma
    • Stage IV Squamous Cell Lung Carcinoma AJCC V7
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 21, 2021

    Urothelial Cancer Trial in Spain (Niraparib plus Cabozantinib)

    Recruiting
    • Urothelial Cancer
    • Niraparib plus Cabozantinib
    • Barcelona, Cataluña, Spain
    • +10 more
    Feb 8, 2022

    Tumors Trial (ABN401)

    Not yet recruiting
    • Neoplasms
    • (no location specified)
    May 21, 2023

    Advanced Gastric Adenocarcinoma Trial in Seoul (Volitinib)

    Completed
    • Advanced Gastric Adenocarcinoma
    • Seoul, Korea, Republic of
      Samsung Medical center
    Jun 13, 2022

    NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)

    Completed
    Has Results
    • Non-small Cell Lung Cancer
    • Beijing, China
    • +43 more
    Oct 13, 2022

    NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

    Not yet recruiting
    • NSCLC
    • +5 more
    • (no location specified)
    Dec 7, 2022

    Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Poland, United

    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • +6 more
    • Cincinnati, Ohio
    • +4 more
    Aug 3, 2022

    Gastric Cancer Trial (Disitamab Vedotin Combined With Sintilimab)

    Not yet recruiting
    • Gastric Cancer
    • Disitamab Vedotin Combined With Sintilimab
    • (no location specified)
    Jan 31, 2023

    Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate

    Not yet recruiting
    • Cancer of Cervix
    • Apoptosis
    • Immunohistochemistry
    • (no location specified)
    Nov 17, 2023

    NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • HS-10241+ Almonertinib
    • Pemetrexed + Cisplatin /Carboplatin
    • (no location specified)
    Oct 29, 2023

    HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen

    Recruiting
    • HER-2 Gene Amplification
    • +4 more
    • chimeric antigen receptor (CAR) T cell therapy
    • Duarte, California
    • +6 more
    Aug 10, 2022

    HER2-overexpressed Advanced Solid Tumors After Progression of

    Not yet recruiting
    • HER2
    • +3 more
    • Disitamab Vedotin
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Dec 14, 2022

    Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)

    Not yet recruiting
    • Lung Non-Small Cell Carcinoma
    • Amivantamab
    • +3 more
    • (no location specified)
    Oct 30, 2023

    STARD3 in Colorectal Cancer: The STAR Study

    Recruiting
    • Colorectal Cancer
      • Aviano, Pordenone, Italy
        Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
      Nov 16, 2023

      Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

      Not yet recruiting
      • Gastric Cancer
      • Disitamab Vedotin
      • +3 more
      • (no location specified)
      Nov 17, 2022

      Breast Cancer Trial in United States (Margetuximab)

      Completed
      Has Results
      • Breast Cancer
      • Margetuximab
      • San Francisco, California
      • +5 more
      Feb 4, 2022

      Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg)

      Completed
      Has Results
      • Carcinoma, Hepatocellular
      • Tepotinib 300 mg
      • +4 more
      • Beijing, Beijing, China
      • +42 more
      Aug 22, 2022